-
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
-
Media Release
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
-
Media Release
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
-
Media Release
US Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US
-
Media Release
US Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US
-
Media Release
Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
-
Media Release
Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
-
Media Release
FDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
-
Media Release
FDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
-
Media Release
Video: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
-
Media Release
Video: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
-
Media Release
Video: FDA approves Exforge HCT® - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill